Institution Leaders
Are you an Executive in the Technology Transfer Office or Dean of Research at your institution? Are you looking to accelerate your academic institution’s output, reputation and impact in medical science?
The increasing unpredictability with traditional sources of funding highlights the increasing importance of collaboration with pharma/device industry. However, good science is not always pursued.
“The issue is not the science.”
“The issue is the positioning.”
PMCL are pharma insiders who will work with you to position your science for industry partnership.
“If pharma isn’t engaging, it’s usually not the science.”
“It’s how it’s being framed and targeted.”
If you are considering partnership with pharma/device industry, that is a good start. But how?
How do smaller and larger companies view our institutions IP and assets differently?
How does pharma industry view risks with their investments?
How can I find which companies would have an interest in our strongest assets?
How can I make my institution a center of choice for research across multiple specialities?
PMCL engagement is customized for each client’s situation. Here are some examples of strategic advisory programs:
“Strategic positioning for institution acceleration”
Why do pharma/device companies seek partnerships with academic institutions?
How different companies may have different perspectives and what does that mean to my positioning
Identifying strengths & gaps
What is the structure of a pharma organization and who do I need in the boardroom
——————-
“Research Center of Excellence”
How and why do pharma companies seek centers of excellence?
What ways can an institution become a preferred center for research?
How can I position my institution to become a center of excellence?
What would be the expectations of my institution from the pharma company?
——————-
“Live Deal with Commercialization”
What do pharma companies consider in making a deal?
Framing your scientific project to be pursued
Key internal stakeholders- what are their perspectives
What sort of risks does pharma consider?
Deal breakers- how to avoid them
——————-